2.1
Isatuximab (Sarclisa, Sanofi) is indicated 'in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant'.
2 Information about isatuximab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for isatuximab.
Price
2.3
The list price of isatuximab is £506.94 per 100 mg/5 ml vial and £2,534.69 per 500 mg/25 ml vial (excluding VAT; BNF online accessed May 2025).
2.4
The company has a commercial arrangement. This makes isatuximab available to the NHS with a discount. The size of the discount is commercial in confidence.
Carbon Reduction Plan
2.5
For information, Sanofi did not disclose its Carbon Reduction Plan for UK carbon emissions.